Sidoti Csr Forecasts Assertio’s Q3 Earnings (NASDAQ:ASRT)

Assertio Holdings, Inc. (NASDAQ:ASRT) – Equities research analysts at Sidoti Csr lowered their Q3 2025 earnings per share estimates for Assertio in a report released on Thursday, March 13th. Sidoti Csr analyst J. Sidoti now anticipates that the company will post earnings per share of $0.00 for the quarter, down from their prior estimate of $0.02. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share. Sidoti Csr also issued estimates for Assertio’s Q4 2025 earnings at $0.00 EPS.

Several other analysts also recently weighed in on ASRT. Industrial Alliance Securities set a $1.75 price objective on Assertio in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Assertio in a report on Monday, December 16th. Finally, StockNews.com lowered shares of Assertio from a “buy” rating to a “hold” rating in a report on Monday.

Assertio Trading Down 1.5 %

Shares of Assertio stock opened at $0.72 on Monday. The firm’s 50-day moving average price is $0.80 and its two-hundred day moving average price is $0.96. The company has a market capitalization of $68.55 million, a price-to-earnings ratio of -0.98, a PEG ratio of 3.25 and a beta of 0.81. The company has a quick ratio of 1.57, a current ratio of 2.01 and a debt-to-equity ratio of 0.30. Assertio has a 12-month low of $0.68 and a 12-month high of $1.80.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ASRT. Captrust Financial Advisors acquired a new position in Assertio in the third quarter valued at approximately $26,000. Stifel Financial Corp bought a new position in shares of Assertio during the 4th quarter worth about $27,000. Commonwealth Equity Services LLC acquired a new stake in shares of Assertio in the 4th quarter valued at about $30,000. Sonora Investment Management Group LLC bought a new stake in Assertio in the 4th quarter valued at about $39,000. Finally, Wealthfront Advisers LLC acquired a new position in Assertio during the 4th quarter worth approximately $53,000. 48.96% of the stock is owned by institutional investors.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.